Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623zct

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:30:14 ON 28 JAN 2005

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:30:18 ON 28 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JAN 2005 HIGHEST RN 820958-11-0
DICTIONARY FILE UPDATES: 26 JAN 2005 HIGHEST RN 820958-11-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\DIA SHI BRADY.str



chain nodes :
11 12 13 14 16 19 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 20 21 22 23 24 25
chain bonds :
7-19 8-14 9-11 9-12 10-16 12-13 24-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
5-7 6-10 7-8 7-19 8-9 8-14 9-10 10-16 12-13 24-26
exact bonds :
9-11 9-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25

G1:C,S

G2:C,O,S,N

G3:C,H

Match level :

STN SEARCH TRANSCRIPT 10/614,539

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
Generic attributes :
26:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR



G1 C,S
G2 C,O,S,N
G3 C,H

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 11:30:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 194 TO ITERATE

100.0% PROCESSED 194 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3045 TO 4715
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 11:31:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4148 TO ITERATE

100.0% PROCESSED 4148 ITERATIONS 104 ANSWERS
SEARCH TIME: 00.00.01

L3 104 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.76	161.97

FILE 'CAPLUS' ENTERED AT 11:31:30 ON 28 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Jan 2005 VOL 142 ISS 6
FILE LAST UPDATED: 27 Jan 2005 (20050127/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L3
L4 7 L3

=> D 1-7 IBIB ABS HITSTR

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:967777 CAPLUS
DOCUMENT NUMBER: 142:48410
TITLE: Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies
AUTHOR(S): Su, Dai-Shi; Markowitz, M. Kristine; Murphy, Kathy L.; Wan, Bang-Lin; Zrada, Matthew M.; Harrell, C. Meacham; O'Malley, Stacy S.; Hess, J. Fred; Ransom, Rick W.; Chang, Ray S.; Wallace, Michael A.; Raab, Conrad E.; Dean, Dennis C.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(24), 6045-6048
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

APP'S



I

AB We have developed an efficient and selective radioligand, the [35S]-radiolabeled dihydroquinoxalinone derivative, I, for an ex vivo receptor occupancy assay in transgenic rats over-expressing the human bradykinin B1 receptor.

IT **714564-55-3P 714564-94-0P 714565-08-9P 714565-23-8P 714565-27-2P 714565-60-3P 714565-98-7P 808770-57-2P**
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(efficient and selective radioligand for bradykinin B1 receptor occupancy studies)

RN 714564-55-3 CAPLUS

CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-94-0 CAPLUS

CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-08-9 CAPLUS

CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-23-8 CAPLUS

CN 2-Quinoxalineacetamide, 1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-27-2 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-60-3 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-1-yl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-98-7 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-N-[2-[4-(4H-1,2,4-triazol-4-yl)phenyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 808770-57-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● HCl

IT 808770-58-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(efficient and selective radioligand for bradykinin B1 receptor occupancy studies)
RN 808770-58-3 CAPLUS
CN 2-Quinoxalineacetamide, N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl-35S)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:750984 CAPLUS
DOCUMENT NUMBER: 141:343321
TITLE: Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist
AUTHOR(S): Ransom, Richard W.; Harrell, Charles M.; Reiss, Duane R.; Murphy, Kathryn L.; Chang, Raymond S. L.; Hess, J. Fred; Miller, Patricia J.; O'Malley, Stacey S.; Hey, Pat J.; Kunapuli, Priya; Su, Dai-Shi; Markowitz, M. Kristine; Wallace, Michael A.; Raab, Conrad E.; Jones, Allen N.; Dean, Dennis C.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.
CORPORATE SOURCE: Department of Molecular Neurology, WP46-300, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: European Journal of Pharmacology (2004), 499(1-2), 77-84
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Compound A (N-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl}-2-[(2R)-1-(2-naphthylsulfonyl)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl]acetamide) is a member of a new class of aryl sulfonamide dihydroquinoxalinone bradykinin B1 receptor antagonists that should be useful pharmacol. tools. Here we report on some of the pharmacol. properties of compound A as well as the characterization of [35S]compound A as the first nonpeptide bradykinin B1 receptor radioligand. Compound A inhibited tritiated peptide ligand binding to the cloned human, rabbit, dog, and rat bradykinin B1 receptors expressed in CHO cells with Ki values of 0.016, 0.050, 0.56, and 29 nM, resp. It was inactive at 10 μM in binding assays with the cloned human bradykinin B2 receptor. In functional antagonist assays with the cloned bradykinin B1 receptors, compound A inhibited agonist-induced signaling with activities consistent with the competition binding results, but had no antagonist activity at the bradykinin B2 receptor. Compound A was also found to be a potent antagonist in a rabbit aorta tissue bath preparation and to effectively block des-Arg9 bradykinin depressor responses in lipopolysaccharide-treated rabbit following i.v. administration. The binding of [35S]compound A was evaluated with the cloned bradykinin B1 receptors. In assays with human, rabbit, and dog receptors, [35S]compound A labeled a single site with Kd values of 0.012, 0.064, and 0.37 nM, resp., and with binding site densities equivalent to those obtained using the conventional tritiated peptide ligands. Binding assays with the cloned rat bradykinin B1 receptor were not successful, presumably due to the low affinity of the ligand for this species receptor. There was no specific binding of the ligand detected in CHO cells expressing the human bradykinin B2 receptor. In assays with the cloned human bradykinin B1 receptor, the pharmacologies of the binding of [35S]compound A and [3H][Leu9]des-Arg10-kallidin were the same. The high signal-to-noise ratio obtained with [35S]compound A will allow this ligand to be a very useful tool for future investigations of the bradykinin B1 receptor.

IT 714564-55-3 714565-13-6
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(pharmacol. characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist)
RN 714564-55-3 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-13-6 CAPLUS
CN 2-Quinoxalineacetamide, N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:531363 CAPLUS
DOCUMENT NUMBER: 141:89112
TITLE: Preparation of quinoxalinones as bradykinin B1 antagonists for the treatment of pain and inflammation.
INVENTOR(S): Su, Dai-shi; Bock, Mark G.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054584	A1	20040701	WO 2003-US39058	20031209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132733	A1	20040708	US 2003-614539	20030707
PRIORITY APPLN. INFO.:			US 2002-433146P	P 20021213
OTHER SOURCE(S):	MARPAT 141:89112			

GI



I



II

APPLICANTS

AB Title compds. I [X = (CH2)mCONRb, (CH2)mNRbCO, (CH2)mCO2, etc.; m = 0-2; Rb = H, alkyl; Y = CO, CO2, SO2, etc.; R1 = (un)substituted (CH2)n-phenyl; n = 0-10; R2 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R3a, R3b = H, halo, alkyl, etc.; R4 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, condensation of ethylene diamine and cyanophenyl II [R = CN], e.g., prepared from di-Me D-aspartate in 5-steps, afforded dihydro-1H-imidazol II [R = C=NCH2CH2NH-] in 51% yield. In human bradykinin B1-B2 receptor binding assays, compds. I exhibited affinity for the B1 receptor at least 10-fold, and preferably over 100-fold, over that for the B2 receptor (sic). Compds. I are claimed useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

IT **714564-55-3P 714564-60-0P 714564-65-5P**
714564-69-9P 714564-79-1P 714564-84-8P
714564-89-3P 714564-94-0P 714564-99-5P
714565-04-5P 714565-08-9P 714565-13-6P
714565-18-1P 714565-23-8P 714565-27-2P

714565-32-9P 714565-38-5P 714565-51-2P
714565-60-3P 714565-64-7P 714565-78-3P
714565-94-3P 714565-98-7P 714566-02-6P
714566-13-9P 714566-22-0P 714566-27-5P
714566-43-5P 714566-61-7P 714566-65-1P
714567-44-9P 714567-54-1P 714567-65-4P
714567-75-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoxalinones as bradykinin B1 antagonists for the treatment of pain and inflammation.)

RN 714564-55-3 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-60-0 CAPLUS
CN Benzeneacetamide, N-[[(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-2-quinoxalinyl]methyl]-4-(4,5-dihydro-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-65-5 CAPLUS

CN 2(1H)-Quinoxalinone, 4-[(3,4-dichlorophenyl)sulfonyl]-3-[2-[[3-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]propyl]sulfonyl]ethyl]-3,4-dihydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-69-9 CAPLUS
CN 2(1H)-Quinoxalinone, 4-[(3,4-dichlorophenyl)sulfonyl]-3-[5-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]pentyl]-3,4-dihydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-79-1 CAPLUS
CN Benzeneacetamide, N-[2-[(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-2-quinoxalinyl]ethyl]-4-(4,5-dihydro-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-84-8 CAPLUS
CN 2-Quinoxalineacetamide, 1-(3,4-difluorobenzoyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-89-3 CAPLUS
CN 2-Quinoxalineacetamide, N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-1-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-94-0 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-99-5 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-4-methyl-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-04-5 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl-35S)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-08-9 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-13-6 CAPLUS
CN 2-Quinoxalineacetamide, N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-18-1 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-7-fluoro-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-23-8 CAPLUS
CN 2-Quinoxalineacetamide, 1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-27-2 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-32-9 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-1-(phenylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-38-5 CAPLUS
CN 2-Quinoxalineacetamide, 1-(3,4-dichlorobenzoyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-51-2 CAPLUS
CN 2-Quinoxalineacetamide, 1-(4-chlorobenzoyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-60-3 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-1-yl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-64-7 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-1-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-78-3 CAPLUS
CN 2-Quinoxalineacetamide, N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylcarbonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-94-3 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-N-[2-[4-(4H-1,2,4-triazol-4-yl)phenyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-98-7 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-N-[2-[4-(4H-1,2,4-triazol-4-yl)phenyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714566-02-6 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714566-13-9 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(5-chloro-2-thienyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-1-yl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714566-22-0 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(4-morpholinyl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714566-27-5 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[4-(1H-imidazol-1-yl)phenyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714566-43-5 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[4-(4-morpholinyl)phenyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714566-61-7 CAPLUS
CN 2-Quinoxalineacetamide, 1-(3-chlorobenzoyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714566-65-1 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-3,4-dihydro-3-oxo-, phenylmethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714567-44-9 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-N-[4-(1-piperazinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714567-54-1 CAPLUS
CN 2-Quinoxalineacetamide, 1-(cyclohexylcarbonyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714567-65-4 CAPLUS
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(methylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714567-75-6 CAPLUS
CN 1(2H)-Quinoxalineacetic acid, 2-[2-[[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-3,4-dihydro-3-oxo-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:892758 CAPLUS
DOCUMENT NUMBER: 139:395948
TITLE: Preparation of sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
INVENTOR(S): Grant, Francine; Bartulis, Sarah; Brogley, Louie; Dappan, Michael S.; Kasar, Ramesh; Khan, Amin; Neitzel, Martin; Pleiss, Michael A.; Thorsett, Eugene D.; Tucker, John; Ye, Michael; Hawkinson, John
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 391 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093245	A1	20031113	WO 2003-US13805	20030502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004147519	A1	20040729	US 2003-429203	20030502
US 2004147520	A1	20040729	US 2003-429917	20030502
PRIORITY APPLN. INFO.:			US 2002-378206P P	20020503
OTHER SOURCE(S):	MARPAT 139:395948			

GI



I



II

AB Title compds. I [wherein n = 0-4; p= 0-1; q = 0-1; Y = O, S, OR8, NHR8, NR8, or SR8; W = O, S, or N; when W = O or S, then q = 0; when W = N, then q = 1; R = (un)substituted (hetero)aryl or heterocyclyl; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, or heterocyclyl; or NR1R2 = (un)substituted (hetero)aryl or heterocyclyl; R3 = independently (un)substituted (cyclo)alkyl, alkenyl, alkynyl, amino, alkoxy, (hetero)aryl(oxy), heterocyclyl(oxy), acyl(oxy), halo, NO2, CN, OH, carboxy, or carbamoyl; R7 = H or (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, heterocyclyl, or acyl(oxy); R8 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, heterocyclyl, or acyl(oxy); with provisos; and pharmaceutically acceptable salts thereof] were prepared as bradykinin antagonists. For example, condensation of 2-[1-(4-chloro-2,5-dimethylbenzenesulfonyl)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl]acetic acid and 4-[2-(tert-butoxycarbonylamino)ethyl]piperidine in the presence of TEA and DPPA in DMF afforded II. Compds. of the invention inhibited the bradykinin B1 receptor in IMR-90 human lung fibroblast cells with IC50 values of 0.1 nM to 10,000 nM. Thus, I are useful for relieving symptoms associated with

bradykinin, including pain, inflammation, bronchoconstriction, cerebral edema, etc. (no data).

IT **625438-79-1P 625438-80-4P 625440-78-0P 625441-13-6P 625441-15-8P 625442-23-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bradykinin B1 antagonist; preparation of (quinoxalinyl)acetamides and related compds. as bradykinin antagonists for treatment of pain, inflammation, and other disorders)

RN 625438-79-1 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-N-[(1R)-2-oxo-1-[[4-(2-pyrimidinyl)phenyl]methyl]-2-(1-pyrrolidinyl)ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625438-80-4 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-N-[(1R)-2-oxo-1-[[4-(2-pyrimidinyl)phenyl]methyl]-2-(1-pyrrolidinyl)ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625440-78-0 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)



RN 625441-13-6 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-N-[(1S)-1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2,3,4-tetrahydro-3-oxo-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 625441-12-5
CMF C34 H37 Cl N6 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625441-15-8 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-N-[(1R)-1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2,3,4-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625442-23-1 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[(1S)-1-[[4-(1H-imidazol-2-yl)phenyl]methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:418208 CAPLUS
DOCUMENT NUMBER: 139:127923
TITLE: Discovery of a Potent, Non-peptide Bradykinin B1 Receptor Antagonist
AUTHOR(S): Su, Dai-Shi; Markowitz, M. Kristine; DiPardo, Robert M.; Murphy, Kathy L.; Harrell, C. Meacham; O'Malley, Stacy S.; Ransom, Richard W.; Chang, Raymond S. L.; Ha, Sookhee; Hess, Fred J.; Pettibone, Douglas J.; Mason, Glenn S.; Boyce, Susan; Freidinger, Roger M.; Bock, Mark G.
CORPORATE SOURCE: Departments of Medicinal Chemistry and Neuroscience, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Journal of the American Chemical Society (2003), 125(25), 7516-7517
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Bradykinin (BK) plays an important role in the pathophysiol. processes accompanying pain and inflammation. Selective bradykinin B1 receptor antagonists have been shown to be anti-nociceptive in animal models and could be novel therapeutic agents for the treatment of pain and inflammation. We have explored chemical modifications in a series of dihydroquinoxalinone sulfonamides to evaluate the effects of various structural changes on biol. activity. The optimization of a screening lead compound, facilitated by a homol. model of the BK B1 receptor, culminated in the discovery of a potent human BK B1 receptor antagonist. Results from site-directed mutagenesis studies and expts. in an animal pain model are presented.

IT **565460-52-8P 565460-53-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(non-peptide bradykinin B1 receptor antagonist)

RN 565460-52-8 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[4-(1H-imidazol-2-yl)phenyl]-3-oxo- (9CI) (CA INDEX NAME)



RN 565460-53-9 CAPLUS
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:76620 CAPLUS
DOCUMENT NUMBER: 138:131142
TITLE: Tetrahydroquinoxalines acting as bradykinin antagonists, their preparation, and their therapeutic use
INVENTOR(S): Beyreuther, Bettina; Hahn, Michael; Kallus, Christopher; Kruger, Joachim; Meier, Heinrich; Reissmuller, Elke; Telan, Leila; Wittka-Nopper, Reilinde; Kroll, Mathias
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007958	A1	20030130	WO 2002-EP7416	20020704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10134721	A1	20030206	DE 2001-10134721	20010717
EP 1411948	A1	20040428	EP 2002-762319	20020704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004536858	T2	20041209	JP 2003-513565	20020704
US 2004235849	A1	20041125	US 2004-483464	20040614
PRIORITY APPLN. INFO.:			DE 2001-10134721 A	20010717

OTHER SOURCE(S): MARPAT 138:131142
AB The invention discloses tetrahydroquinoxaline derivs., a method for producing them, and the use thereof for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of painful conditions. The compds. have an affinity for the bradykinin-1 receptor.
IT **491847-64-4P 491848-17-0P 491848-18-1P 491848-19-2P 491848-20-5P 491848-21-6P 491848-22-7P 491848-25-0P 491848-41-0P 491848-42-1P 491848-43-2P 491848-44-3P 491848-45-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetrahydroquinoxaline bradykinin antagonists, preparation, and therapeutic use)
RN 491847-64-4 CAPLUS
CN Piperazine, 1-(3-methylphenyl)-4-[[1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 491848-17-0 CAPLUS
CN Piperazine, 1-(2-methylphenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-18-1 CAPLUS
CN Piperazine, 1-(2,4-difluorophenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-19-2 CAPLUS
CN Piperazine, 1-(4-fluorophenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-20-5 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-21-6 CAPLUS
CN Piperazine, 1-[2-(methylthio)phenyl]-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-22-7 CAPLUS
CN Piperazine, 2-methyl-1-(3-methylphenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-25-0 CAPLUS
CN Piperazine, 2-methyl-1-phenyl-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-41-0 CAPLUS
CN Piperazine, 1-(2,6-dimethylphenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 491848-42-1 CAPLUS
CN Piperazine, 1-(3-chlorophenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-43-2 CAPLUS
CN Piperazine, 1-(3-methoxyphenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-44-3 CAPLUS
CN Piperazine, 1-(3,5-dichlorophenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-45-4 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-[[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:605386 CAPLUS
DOCUMENT NUMBER: 121:205386
TITLE: Preparation of quinoxalines as neuroprotectants for cerebral ischemia
INVENTOR(S): Fujiwara, Shigeki; Takai, Haruki; Ikeda, Junichi; Kubo, Kazuhiro
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

* CLOSEST PRIOR ART

JP 05331151 A2 19931214 JP 1992-136752 19920528
PRIORITY APPLN. INFO.: JP 1992-136752 19920528
OTHER SOURCE(S): MARPAT 121:205386
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Quinoxaline derivs., e. g. I [A = (substituted) aryl, aralkyl, etc.; R3 = H, (substituted) alkyl, aralkyl; n = 1 - 5; DE = N:C, or R4NC; R4 = H, (substituted) arylsulfonyl, etc.], are prepared A mixture of quinoxaline II and 1-(2-methoxyphenyl)piperazine in THF containing tetra-Bu ammonium bromide and Et3N was refluxed for 40 h to give quinoxalines III and IV (R = H). IV (R = Me) showed min. ED of 3 mg/kg against brain ischemia in mice.

IT **157861-51-3P 157861-52-4P 157861-53-5P**
157861-54-6P 157861-55-7P 157861-56-8P
157861-57-9P 157861-58-0P 157861-61-5P
157861-62-6P 157861-63-7P 157861-64-8P
157861-65-9P 157861-66-0P 157861-67-1P
157861-68-2P 157861-69-3P 157861-70-6P
157861-71-7P 157861-72-8P 157861-73-9P
157861-74-0P 157861-75-1P 157861-76-2P
157861-77-3P 157861-78-4P 157861-79-5P
157861-80-8P 157861-81-9P 157861-82-0P
157861-83-1P 157861-84-2P 157861-85-3P
157861-86-4P 157861-87-5P 157861-88-6P
157861-89-7P 157861-90-0P 157861-91-1P
157861-92-2P 157861-93-3P 157861-94-4P
157861-95-5P 157861-96-6P 157861-97-7P
157861-98-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as neuroprotective agent)

RN 157861-51-3 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1-methyl-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-52-4 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1-methyl-4-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-53-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-methyl-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-54-6 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-methyl-4-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-55-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-56-8 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(phenylsulfonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 157861-57-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-58-0 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-61-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-62-6 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(methylsulfonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 157861-63-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-64-8 CAPLUS
CN 2(1H)-Quinoxalinone, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-65-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-66-0 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-67-1 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-methyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-68-2 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-methyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-69-3 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methylpropyl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 157861-70-6 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methylpropyl)-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-71-7 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-72-8 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-73-9 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-4-propyl-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-74-0 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-4-propyl-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-75-1 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-butyl-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-76-2 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-butyl-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 157861-77-3 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-(cyclopropylmethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-78-4 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-(cyclopropylmethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-79-5 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-(cyclohexylmethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-80-8 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-(cyclohexylmethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-81-9 CAPLUS
CN 1(2H)-Quinoxalinepropanoic acid, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2-oxo-4-[(2-propenyloxy)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 157861-82-0 CAPLUS
CN 1(2H)-Quinoxalinepropanoic acid, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2-oxo-4-[(2-propenyloxy)carbonyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 157861-83-1 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-(2-ethoxyethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-84-2 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-(2-ethoxyethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-85-3 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-4-(phenylmethyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-86-4 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-4-(phenylmethyl)-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-87-5 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-88-6 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-89-7 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-butyl-2-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-90-0 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 4-butyl-2-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-91-1 CAPLUS
CN 1(2H)-Quinoxalinepropanoic acid, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-2-oxo-4-[(2-propenyloxy)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 157861-92-2 CAPLUS
CN 1(2H)-Quinoxalinepropanoic acid, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-2-oxo-4-[(2-propenyloxy)carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-93-3 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-4-(phenylmethyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-94-4 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-4-(phenylmethyl)-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-95-5 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-96-6 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157861-97-7 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 157861-98-8 CAPLUS
CN 1(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.93	197.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-5.11

STN INTERNATIONAL LOGOFF AT 11:33:08 ON 28 JAN 2005